Features Partner Sites Information LinkXpress
Sign In
Demo Company

Theraclone Partners with Gilead Sciences for Neutralizing HIV Antibody Technology

By BiotechDaily International staff writers
Posted on 13 Aug 2014
Print article
Theraclone Sciences, Inc. (Seattle, WA, USA), a therapeutic antibody discovery and development company, has entered into an agreement with Gilead Sciences, Inc. (Foster City, CA, USA), under which Gilead received an exclusive license to develop and commercialize products integrating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV.

These neutralizing antibodies (bNAbs) were discovered in collaboration with the International AIDS Vaccine Initiative (IAVI; New York, NY, USA) and The Scripps Research Institute (La Jolla, CA, USA) using Theraclone’s proprietary I-STAR (in-situ therapeutic antibody rescue) technology. The I-STAR technology allows for the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biologic functions and activities.

“Through our innovative I-STAR technology, we are able to uncover unique antibodies that have the capacity to neutralize viruses, such as HIV, that are known to mutate and evade current therapies,” said Clifford J. Stocks, chief executive officer of Theraclone. “We look forward to collaborating with Gilead on the development of new therapies to address HIV infection.”

Theraclone is a biopharmaceutical company focused on the discovery and development of novel, monoclonal antibody therapeutics for diseases that are deemed a considerable health threat. Theraclone utilizes its proprietary antibody discovery technology, I-STAR to identify rare fully human antibodies, from immunologically relevant human study participants, that may be developed into antibody product candidates that are potentially safer and more effective than current therapies, or that address an unmet need.

With a primary focus on cancer and infectious disease, Theraclone has a range of antibody programs at preclinical and clinical development stage targeting serious medical disorders with a significant unmet medical need including: triple negative and endocrine treatment-resistant HER-2-negative breast cancer; infectious disease-associated cancers; immune profiling of cancer patients treated with immunomodulators, checkpoint inhibitors or cancer vaccines; and Gram-negative multidrug resistant bacteria.

TCN-032 is a recombinant fully human monoclonal antibody for the treatment of patients hospitalized with serious influenza that has shown statistically significant reduction in viral load and improvement of clinical symptom scores in a phase 2a viral challenge model.

Related Links:

Theraclone Sciences
Gilead Sciences
International AIDS Vaccine Initiative

Print article



view channel
Image: Sequencing and analysis of the pineapple genome offers new insights into the evolution of plant drought-resistance, different types of photosynthesis, and circadian clock regulatory adaptations (Photo courtesy of Robert E. Paull, University of Hawaii).

Insights into Evolution of Drought-Tolerance Revealed by Pineapple Genome

Upon sequencing its genome, scientists begin to home in on genes and pathways that enable the pineapple plant to thrive in water-limited environments and open a new window on CAM photosynthesis, circadian... Read more


view channel
Image: A partially completed three-dimensional printed airway from nostril to trachea with fine structure of the nasal cavity showing (Photo courtesy of Dr. Rui Ni, Pennsylvania State University).

The Structure of the Nasal Cavity Channels Food Smells into the Nose and Avoids the Lungs

Three-dimensional printing technology was used to create a model of the nasal cavity that enabled researchers to demonstrate why the smell of food goes into the nose rather than down into the lungs.... Read more


view channel
Image: Structure of the protein encoded by the CFTR gene (Photo courtesy of Wikimedia Commons).

Advanced Gene Therapy Cures Cystic Fibrosis in Culture and Mouse Models

Improvements in gene therapy technology enabled restoration of ion channel function in cultures of cells from cystic fibrosis (CF) patients and in a CF mouse model. In cystic fibrosis, mutations of... Read more

Lab Technologies

view channel
Image:  The BioSpa 8 Automated Incubator (Photo courtesy of BioTek Instruments).

Smart Incubator System Automates Live Cell Assay Operations

A new instrument that automates laboratory workflow by linking microplate washers and dispensers with readers and imaging systems is now available for biotech and other life sciences researchers.... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.